Cargando…

Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study

BACKGROUND: Golimumab (GLM) has been reported to have lower immunogenicity than do other TNF inhibitors used for treating rheumatoid arthritis (RA). We previously found a prolonged effect of and improvement similar to that associated with infliximab (IFX) after switching to subcutaneous GLM (GLM-SC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakabayashi, Hiroki, Nagao, Nobuto, Inada, Hitoshi, Nishioka, Yosuke, Hasegawa, Masahiro, Nishioka, Kusuki, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363693/
https://www.ncbi.nlm.nih.gov/pubmed/34173221
http://dx.doi.org/10.1007/s40268-021-00355-2
_version_ 1783738396276948992
author Wakabayashi, Hiroki
Nagao, Nobuto
Inada, Hitoshi
Nishioka, Yosuke
Hasegawa, Masahiro
Nishioka, Kusuki
Sudo, Akihiro
author_facet Wakabayashi, Hiroki
Nagao, Nobuto
Inada, Hitoshi
Nishioka, Yosuke
Hasegawa, Masahiro
Nishioka, Kusuki
Sudo, Akihiro
author_sort Wakabayashi, Hiroki
collection PubMed
description BACKGROUND: Golimumab (GLM) has been reported to have lower immunogenicity than do other TNF inhibitors used for treating rheumatoid arthritis (RA). We previously found a prolonged effect of and improvement similar to that associated with infliximab (IFX) after switching to subcutaneous GLM (GLM-SC) for control of RA activity or adverse events. Thus, this study aimed to evaluate the continued maintenance of treatment efficacy and safety for > 2 years by switching to GLM-SC in RA patients with low disease activity or in remission after previous treatment with another tumor necrosis factor (TNF) inhibitor. METHODS: Thirty-two patients treated with etanercept or infliximab were switched to GLM-SC and maintained low disease activity. The patients were divided into two groups (GLMq4w and GLMq8w) through discussion with each patient, considering their general condition and convenience. The groups included patients with low disease activity or in remission who switched to 50-mg GLM therapy at 4-week and 8-week intervals, respectively. RESULTS: The mean DAS28-ESR and DAS-CRP values in the GLMq4w group (17 patients) and GLMq8w group (15 patients) were maintained from baseline throughout the 104-week treatment period. Two patients from the GLMq4w group showed disease flaring to moderate disease activity. No serious adverse events occurred, and the treatment continuation rate at 104 weeks was 100% in both groups. After > 2 years of treatment, three patients in the GLMq8w group and one patient in the GLMq4w group discontinued GLM treatment due to relapse or complications. The 5-year survival rates were 88.2% and 75.5% in the GLMq4w and GLMq8w groups, respectively. The average treatment duration was 5.0 (2.0–7.5) years. CONCLUSION: Administration of GLM-SC at 4-week and 8-week intervals after switching from TNF inhibitors showed sustained long-term efficacy and acceptable safety in RA patients with low disease activity.
format Online
Article
Text
id pubmed-8363693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83636932021-08-30 Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study Wakabayashi, Hiroki Nagao, Nobuto Inada, Hitoshi Nishioka, Yosuke Hasegawa, Masahiro Nishioka, Kusuki Sudo, Akihiro Drugs R D Short Communication BACKGROUND: Golimumab (GLM) has been reported to have lower immunogenicity than do other TNF inhibitors used for treating rheumatoid arthritis (RA). We previously found a prolonged effect of and improvement similar to that associated with infliximab (IFX) after switching to subcutaneous GLM (GLM-SC) for control of RA activity or adverse events. Thus, this study aimed to evaluate the continued maintenance of treatment efficacy and safety for > 2 years by switching to GLM-SC in RA patients with low disease activity or in remission after previous treatment with another tumor necrosis factor (TNF) inhibitor. METHODS: Thirty-two patients treated with etanercept or infliximab were switched to GLM-SC and maintained low disease activity. The patients were divided into two groups (GLMq4w and GLMq8w) through discussion with each patient, considering their general condition and convenience. The groups included patients with low disease activity or in remission who switched to 50-mg GLM therapy at 4-week and 8-week intervals, respectively. RESULTS: The mean DAS28-ESR and DAS-CRP values in the GLMq4w group (17 patients) and GLMq8w group (15 patients) were maintained from baseline throughout the 104-week treatment period. Two patients from the GLMq4w group showed disease flaring to moderate disease activity. No serious adverse events occurred, and the treatment continuation rate at 104 weeks was 100% in both groups. After > 2 years of treatment, three patients in the GLMq8w group and one patient in the GLMq4w group discontinued GLM treatment due to relapse or complications. The 5-year survival rates were 88.2% and 75.5% in the GLMq4w and GLMq8w groups, respectively. The average treatment duration was 5.0 (2.0–7.5) years. CONCLUSION: Administration of GLM-SC at 4-week and 8-week intervals after switching from TNF inhibitors showed sustained long-term efficacy and acceptable safety in RA patients with low disease activity. Springer International Publishing 2021-06-25 2021-09 /pmc/articles/PMC8363693/ /pubmed/34173221 http://dx.doi.org/10.1007/s40268-021-00355-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Short Communication
Wakabayashi, Hiroki
Nagao, Nobuto
Inada, Hitoshi
Nishioka, Yosuke
Hasegawa, Masahiro
Nishioka, Kusuki
Sudo, Akihiro
Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
title Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
title_full Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
title_fullStr Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
title_full_unstemmed Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
title_short Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
title_sort long-term maintenance of golimumab effectiveness for injection spacing in rheumatoid arthritis patients with low disease activity who previously received other tnf inhibitors: minimum 2-year data from an observational study
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363693/
https://www.ncbi.nlm.nih.gov/pubmed/34173221
http://dx.doi.org/10.1007/s40268-021-00355-2
work_keys_str_mv AT wakabayashihiroki longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy
AT nagaonobuto longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy
AT inadahitoshi longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy
AT nishiokayosuke longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy
AT hasegawamasahiro longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy
AT nishiokakusuki longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy
AT sudoakihiro longtermmaintenanceofgolimumabeffectivenessforinjectionspacinginrheumatoidarthritispatientswithlowdiseaseactivitywhopreviouslyreceivedothertnfinhibitorsminimum2yeardatafromanobservationalstudy